Toward the potential cure of leukemias in the next decade

Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial

(2018) Anna Candoni et al.   AMERICAN JOURNAL OF HEMATOLOGY

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

(2018) Elias Jabbour et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial

(2018) Jorge E. Cortes et al.   BLOOD

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

(2018) Nicola Gökbuget et al.   BLOOD

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

(2018) Hagop Kantarjian et al.   LANCET ONCOLOGY

Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes

(2018) Naval Daver et al.   LEUKEMIA

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

(2018) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

(2018) Elias Jabbour et al.   JAMA Oncology

High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in Adults

(2017) Kathryn G. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

(2017) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

(2017) Uwe Platzbecker et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

(2017) A Hochhaus et al.   LEUKEMIA

The emerging role of immune checkpoint based approaches in AML and MDS

(2017) Prajwal Boddu et al.   LEUKEMIA & LYMPHOMA

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

(2016) Michael E. Rytting et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

(2016) Nitin Jain et al.   BLOOD

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

(2016) Yasmin Abaza et al.   BLOOD

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

(2016) Philippe Rousselot et al.   BLOOD

Moving treatment-free remission into mainstream clinical practice in CML

(2016) Timothy P. Hughes et al.   BLOOD

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

(2016) Michael R. Grever et al.   BLOOD

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

(2016) Dai Chihara et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

(2016) Koji Sasaki et al.   CANCER

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

(2016) Vincent Ribrag et al.   LANCET

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial

(2016) B Patel et al.   LEUKEMIA

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

(2016) Sébastien Maury et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia

(2016) Yuan-Fang Liu et al.   EBioMedicine

Acute myeloid leukemia-Major progress over four decades and glimpses into the future

(2015) Hagop Kantarjian   AMERICAN JOURNAL OF HEMATOLOGY

Monoclonal antibodies in acute lymphoblastic leukemia

(2015) E. Jabbour et al.   BLOOD

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

(2015) P. A. Thompson et al.   BLOOD

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

(2015) K. Fischer et al.   BLOOD

A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

(2015) Alan K. Burnett et al.   BLOOD

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

(2015) Tapan M. Kadia et al.   CANCER

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) Farhad Ravandi et al.   CANCER

New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

(2015) Elias Jabbour et al.   CANCER

Progress in Acute Myeloid Leukemia

(2015) Tapan M. Kadia et al.   Clinical Lymphoma Myeloma & Leukemia

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) N. Daver et al.   HAEMATOLOGICA

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

(2015) Elias Jabbour et al.   LANCET ONCOLOGY

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

(2015) Christoph Röllig et al.   LANCET ONCOLOGY

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

(2015) Alan K Burnett et al.   LANCET ONCOLOGY

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

(2015) Juliana M. Benito et al.   Cell Reports

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) N. Daver et al.   HAEMATOLOGICA

Toward Individualized Therapy in Acute Myeloid Leukemia

(2015) Tapan M. Kadia et al.   JAMA Oncology

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

(2014) Gautam Borthakur et al.   AMERICAN JOURNAL OF HEMATOLOGY

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

(2014) D. Hoelzer et al.   BLOOD

The Leukemias: A Half-Century of Discovery

(2014) Emil J. Freireich et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of Children With BCR-ABL1–Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease

(2014) Kathryn G. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

A new dawn for gemtuzumab ozogamicin?

(2014) Mohamed A Kharfan-Dabaja   LANCET ONCOLOGY

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

(2014) Jan A Burger et al.   LANCET ONCOLOGY

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

(2014) Robert K Hills et al.   LANCET ONCOLOGY

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199

(2014) T. N. Chonghaile et al.   Cancer Discovery

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

(2013) Aziz Nazha et al.   AMERICAN JOURNAL OF HEMATOLOGY

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

(2013) A. K. Fielding et al.   BLOOD

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

(2013) J. D. Rosenberg et al.   BLOOD

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

(2013) Hagop Kantarjian et al.   CANCER

Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial

(2013) Hong-Hu Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

(2013) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

(2013) Roelof Willemze et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

(2013) Susan O'Brien et al.   LANCET ONCOLOGY

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

(2013) Francesco Lo-Coco et al.   NEW ENGLAND JOURNAL OF MEDICINE

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

(2012) H. J. Iland et al.   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Acute promyelocytic leukemia: A population-based study on incidence and survival in the United States, 1975-2008

(2012) Yiming Chen et al.   CANCER

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2012) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study

(2012) Jerzy Holowiecki et al.   JOURNAL OF CLINICAL ONCOLOGY

Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia

(2012) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

(2012) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older

(2012) Claude Gardin et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study

(2011) W.-Y. Au et al.   BLOOD

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

(2011) F. Ravandi et al.   BLOOD

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

(2011) G. Avvisati et al.   BLOOD

Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia

(2011) Ardeshir Ghavamzadeh et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712

(2011) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

(2010) J. A. Pollard et al.   BLOOD

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

(2010) F. Lo-Coco et al.   BLOOD

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

(2010) B. L. Powell et al.   BLOOD

Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

(2010) Cecile Pautas et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00

(2010) Renato Bassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data

(2010) Vikram Mathews et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid Leukemia

(2010) Andrea Corbacioglu et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

(2010) Deborah A. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10

(2009) Franco Mandelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

(2009) David Grimwade et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2009) Kirk R. Schultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

(2009) Françoise Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

(2008) W. Stock et al.   BLOOD

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

(2008) M. A. Sanz et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival

(2008) Gautam Borthakur et al.   CANCER

Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

(2008) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY